Marnetto Fabiana, Granieri Letizia, Valentino Paola, Capobianco Marco, Pautasso Marisa, Bertolotto Antonio
Clinical Neurobiology Unit, Regional Referring Multiple Sclerosis Centre (CRESM), Neuroscience Institute Cavalieri Ottolenghi (NICO), University Hospital San Luigi Gonzaga, Orbassano, Turin, Italy; Clinical Neurology Unit, Regional Referring Multiple Sclerosis Centre (CReSM), University Hospital San Luigi Gonzaga,Orbassano, Turin, Italy.
Clinical Neurology Unit, Regional Referring Multiple Sclerosis Centre (CReSM), University Hospital San Luigi Gonzaga,Orbassano, Turin, Italy.
J Neuroimmunol. 2014 Dec 15;277(1-2):127-33. doi: 10.1016/j.jneuroim.2014.09.008. Epub 2014 Sep 20.
We compared pre-amplification (PA) RT-PCR blood CD19 mRNA quantification with flow cytometry (FC), to personalize rituximab re-treatment in neuromyelitis optica spectrum disorders (NMOSDs) patients. 47 blood samples from 3 NMOSDs patients were studied. PA-RT-PCR quantified CD19 in all samples, and a positivity threshold was defined, whereas CD19+ B cells were under threshold in 31/47 samples by FC. In all samples where CD19+ B cells were above FC threshold, they resulted above the PA-RT-PCR threshold. CD19 mRNA was above threshold in 8 other samples, resulted negative by FC, and preceded the FC positivity in 7/8 samples by 1-3 months, showing major sensitivity.
我们将预扩增（PA）逆转录聚合酶链反应（RT-PCR）对血液中CD19 mRNA的定量分析与流式细胞术（FC）进行比较，以实现视神经脊髓炎谱系障碍（NMOSD）患者利妥昔单抗再治疗的个体化。研究了3例NMOSD患者的47份血液样本。PA-RT-PCR对所有样本中的CD19进行了定量，并定义了阳性阈值，而通过FC检测，47份样本中有31份样本中的CD19+B细胞低于阈值。在所有CD19+B细胞高于FC阈值的样本中，其结果也高于PA-RT-PCR阈值。另外8份样本中CD19 mRNA高于阈值，但FC检测结果为阴性，且在8份样本中有7份样本中，CD19 mRNA在FC检测呈阳性前1至3个月就高于阈值，显示出更高的敏感性。
Zotero 插件